Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 18, 2020 - Issue 8
Submit an article Journal homepage
103
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Role of Ribavirin in the Era of Direct–Acting Antiviral Therapies of Chronic Hepatitis C

Omkolsoum Alhaddada Department of Hepatology, National Liver Institute, Menoufia University, Shebin El-kom, EgyptView further author information
,
Ahmed Wahba Department of Hepatology, National Liver Institute, Menoufia University, Shebin El-kom, EgyptView further author information
,
Alyaa Sabrya Department of Hepatology, National Liver Institute, Menoufia University, Shebin El-kom, EgyptView further author information
,
Fatma Khalilb Department of Microbiology and Immunology, National Liver Institute, Menoufia University, Shebin El-kom, EgyptView further author information
,
Dalia Elsabaawyc Department of Clinical Pharmacy, Pharmacy College, Menoufia University, Shebin El-kom, EgyptView further author information
,
Helmy Elshazlya Department of Hepatology, National Liver Institute, Menoufia University, Shebin El-kom, EgyptView further author information
,
Nashwa SheblView further author information
,
Mohamed Radya Department of Hepatology, National Liver Institute, Menoufia University, Shebin El-kom, EgyptView further author information
&
Maha Elsabaawya Department of Hepatology, National Liver Institute, Menoufia University, Shebin El-kom, EgyptCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3110-1547View further author information
ORCID Icon show all
Pages 817-822 | Received 19 Oct 2019, Accepted 17 Apr 2020, Published online: 13 May 2020

References

  • Reichard O, Andersson J, Schvarcz R. Weiland O: ribavirin treatment for chronic hepatitis C. Lancet. 1991;337:1058–1061.
  • Reddy K, Shiffman M, Rodriguez-Torres M, et al. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology. 2010;139:1972–1983.
  • Hoofnagle J, Feld J. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Hepatology. 2005;436(7053):967–972.
  • Asselah T, Hezode C, Zadeiki N, et al. ENDURANCE-4: efficacy and safety of ABT-493/ABT-530 treatment in patients with chronic HCV genotype 4, 5, or 6 infection. Hepatology. 2016;64(S1):63.
  • Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol. 2017;67:263–271.
  • Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486–504.
  • Feld JJ, Jacobson IM, Sulkowski MS, et al. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int. 2017;37(1):5–18.
  • European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199–236.
  • European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018 Aug;69(2):461–511.
  • Shiha G, El-Basiouny M, Soliman R, et al. Sofosbuvir plus ribavirin for treatment-naïve chronic HCV genotype 4 patients: real-life experience. Med J Viral Hep. 2016;2.1(1):1–8.
  • Bourlière M, Benali S, Ansaldi C, et al. Optimal therapy of genotype-2 chronic hepatitis C: what’s new? Liver Int. 2015;35(Suppl 1):21–26.
  • Ahmed O, Safwat E, Khalifa M, et al. Sofosbuvir plus daclatasvir in treatment of chronic hepatitis c genotype 4 infection in a cohort of Egyptian patients: an experiment the size of Egyptian village. Int J Hepatol. Article ID 9616234. 2018;5. DOI:10.1155/2018/9616234.
  • Gayam V, Khalid M, Mandal AK, et al. Direct-acting antivirals in chronic hepatitis c genotype 4 infection in community care setting. Gastroenterology Res. 2018;11(2):130–137.
  • El-Khayat HR, Fouad YM, Maher M, et al. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. Gut. 2017;66(11):2008–2012.
  • Nyström K, Wanrooij PH, Waldenström J, et al. Inosine triphosphate pyrophosphatase dephosphorylates ribavirin triphosphate and reduced enzymatic activity potentiates mutagenesis in hepatitis C virus. J Virol. 2018;92(19):e01087–18. DOI:10.1128/JVI.01087-18.
  • Rembeck K, Waldenström J, Hellstrand K, et al. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology. 2014;59(6):2131–2139.
  • El-Edel R, Hendy O, Essa E, et al. Inosine triphosphate pyrophosphatase gene polymorphisms and ribavirin-induced Anemia in HCV patients. J Mol Biomark Diagn. 2017;8:360.
  • Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77‐ 87.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.